All In Biotech

Drug Trial Radar · NCT06594393

A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study

A Randomized, Double-blind, Vehicle-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Topically Applied TCP-25 in Patients With Epidermolysis Bullosa

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Jan 30, 2026

Primary completion

Jun 30, 2027

Study completion Jun 30, 2027

Sponsor

Lead sponsor
Xinnate ABIndustry
Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 4 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, double-blind, randomized, vehicle-controlled study designed to evaluate efficacy, safety, and tolerability of topically applied TCP-25 gel in patients with confirmed DEB or JEB. The study will implement intrasubject randomization, ie, a pair of matching index wounds will be randomly assigned to be treated with a local application of either TCP 25 gel or vehicle gel.

Conditions

  • Epidermolysis Bullosa (EB)
  • Dystrophic Epidermolysis Bullosa
  • Junctional Epidermolysis Bullosa

Interventions

  • TCP-25 gelDrug

    Topical gel

  • Vehicle (placebo)Drug

    Placebo gel

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Open wound areaTime frame: 56 days

Locations

13 sites in 7 countries. Site status is shown where the registry gives one.

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio · Recruiting

  • Hopital St Louis

    Paris, France · Recruiting

  • Andreas Syngros Hospital of Veneral & Dermatological Diseases

    Athens, Greece · Recruiting

  • Hospital Of Skin And Venereal Diseases of Thessaloniki

    Thessaloniki, Greece · Recruiting

  • Hospital

    Modena, Italy · Recruiting

  • IDI Istituto Dermopatico dell'Immacolata IRCCS

    Rome, Italy · Recruiting

  • University hospital

    Gdansk, Poland · Recruiting

  • Dermoklinika Centrum Medyczne

    Lodz, Poland · Recruiting

  • Hospital Clinic de Barcelona

    Barcelona, Spain · Recruiting

  • Hospital Univ La Paz

    Madrid, Spain · Recruiting

  • San Joan de Deu, SJD Children's hospital Barcelona

    Barcelona, Catalonia, Spain · Recruiting

  • Akademiska sjukhuset

    Uppsala, Sweden · Recruiting

  • University hospital

    Lund, Skåne County, Sweden · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.